Lower Limb Amputations: Invokana / Farxiga / Jardiance / Invokamet / Xigduo / Glyxambi / Synjardy / Qtern / Steglatro / Steglujan / Segluromet
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The diabetes Type-2 drugs Invokana, Farxiga, and Jardiance, as well as Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet have been associated with these various medical complications as drug side effects:
- Foot or Toe(s) Amputations
- Leg Amputations
- Fournier’s Gangrene
- Acute Kidney Injury (AKI)
- Kidney Failure / Renal Failure
- Kidney Damage
- Diabetic Ketoacidosis (DKA)
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed any of the medical conditions listed above.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About These Drugs
New medical evidence indicates that lower limb amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date.
We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as Invokana and other similar diabetes drugs from this October 2, 2018 Medscape Medical News report, “SGLT2 Inhibitor-Amputation Link in Diabetes — Is it Hypovolemia?”:
To read more of this article, click below:
The mechanism behind the finding of an increased risk of lower-limb amputation in patients taking [Invokana (canagliflozin)] in the Canagliflozin Cardiovascular Assessment Study (CANVAS) has been much debated. Findings from observational trials of [Invokana (canagliflozin)] have conflicted regarding the amputation risk, and the effect hasn’t been seen with other SGLT2 inhibitors.
But, assuming the amputation risk is a class effect, one theory about the mechanism is that the reduction in plasma volume from SGLT2 inhibitors could lead to decreased perfusion, especially in patients who already have reduced lower limb perfusion. “If true, we hypothesized that diuretics would show a similar safety profile,” [explained Ronan Roussel, MD, PhD, chief of the endocrinology, diabetes, and nutrition department at Group Hôpital Bichat, AP-HP, Paris, France]….
“This is a strong signal,” he told Medscape Medical News in an interview, adding that the data suggest diuretics should be used with caution in patients who are at increased risk for amputation, such as those with critical ischemia.
As background, some diabetic patients at the highest risk of amputations are those with peripheral arterial disease or foot ulcers.
Given the increasing medical evidence that lower limb (leg, foot, toes) amputations are a drug-class side effect of SGLT-2 inhibitors, we continue to investigate amputation drug injury cases for patients using Invokana, Farxiga, Jardiance, and similar newer diabetes medications.[Read article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
- Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
- Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
- Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
- New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
- Invokana – Amputations: No Explanation Yet As Regards “How” And “Why”
- “Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
- FDA Reports Show Extent And Nature of Invokana-Amputation Side Effect
- Invokana Gets “Black-Box Warning” For Risk Of Leg And Foot Amputations
- Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
- Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
- Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
- New Federal Court Multidistrict Litigation (MDL) For Farxiga Lawsuits
- Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada
- December 2016: FDA Requires Safety Warnings Label Change For Jardiance
- Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
- Invokana / Farxiga / Jardiance: UTIs Then Urosepsis And Pyelonephritis
- Invokana / Farxiga / Jardiance: Amputations; Lactic Acidosis; Ketoacidosis
- FDA: Acute Kidney Injury Due To Invokana, Invokamet, Farxiga, Xigduo
- Stroke, DVT, Pulmonary Embolism, And Kidney Damage Linked To Invokana
- When Used By Type 1 Diabetes Patients, Invokana Can Cause Ketoacidosis
- Invokana Cases Involving Diabetic Ketoacidosis And Kidney Side Effects
- EMA Says Invokana / Farxiga /Jardiance Linked To Diabetic Ketoacidosis
- FDA Adds New Ketoacidosis Side Effect Warnings To Invokana Drug Label
- Invokana Label Gets New Warnings About Increased Bone Fracture Risks
- Despite Benefits Of Jardiance, There Are Still Safety Concerns
- Invokana Lawsuits Filed While FDA Investigates Side Effects Reports
- Farxiga / Jardiance / Invokana: Ketoacidosis and Kidney Failure
- Invokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic Ketoacidosis Events Is Associated With Increased Risk of Death
- May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana, Farxiga, And Jardiance, With Label Changes Possible
List of SGLT2 Inhibitors
|Drug Name||Active Ingredient(s)||Drug Manufacturer||FDA Approval Date|
|Invokamet||canagliflozin / metformin||Janssen Pharmaceuticals||2014|
|Invokamet XR||canagliflozin / metformin extended-release||Janssen Pharmaceuticals||2016|
|Xigduo XR||dapagliflozin / metformin extended-release||AstraZeneca Pharmaceuticals||2014|
|Qtern||dapagliflozin / saxagliptin||AstraZeneca Pharmaceuticals||2017|
|Jardiance||empagliflozin||Boehringer Ingelheim Pharmaceuticals||2014|
|Glyxambi||empagliflozin / linagliptin||Boehringer Ingelheim Pharmaceuticals||2015|
|Synjardy||empagliflozin / metformin hydrochloride||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2015|
|Synjardy XR||empagliflozin / metformin hydrochloride extended-release||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2016|
|Steglatro||ertugliflozin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Steglujan||ertugliflozin / sitagliptin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Segluromet||ertugliflozin / metformin hydrochloride||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
All content by attorney Tom Lamb